CardioFocus kicks off EU atrial fibrillation trial

CardioFocus is launching a multi-center trial in Europe, testing its HeartLight balloon-based ablation system on 150 patients with drug-refractory, persistent atrial fibrillation. The study will test CardioFocus' device against standard radiofrequency ablation, completing enrollment by next May and planning a one-year follow-up. Meanwhile, CardioFocus is in the midst of a U.S. trial for FDA approval, aiming to wrap up enrollment this year. More

Suggested Articles

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.

Cybernet Manufacturing, maker of medical-grade computer monitors, has unveiled a new, large touchscreen designed to protect against infections.

A startup has raised $12 million to fund its real-time system for monitoring patients undergoing dialysis at home and calling in complications.